DeepMed Research

Laboratorios Sophia, S.A. de C.V.

🇲🇽Mexico

Country: 🇲🇽Mexico

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Non-inferiority Between Manzanilla Sophia® and Meticel Ofteno® 0.5% for Providing a Relief Sensation to the Eyes.

Phase 4

Not yet recruiting

Conditions: Ophthalmological Agent Toxicity

Interventions: Drug: Manzanilla Sophia®
Drug: Meticel Ofteno® 0.5%

First Posted Date: 2025-03-05

Last Posted Date: 2025-03-05

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 168

Registration Number: NCT06859476

Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children.

Phase 3

Recruiting

Conditions: Myopia
Myopia, Progressive

Interventions: Drug: Alleance®
Drug: Placebo

First Posted Date: 2024-04-29

Last Posted Date: 2025-03-21

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 123

Registration Number: NCT06389110

Locations: 🇲🇽
Innovación Y Desarrollo En Ciencias de La Salud S de Rl de Cv, Mexico City, Mexico

Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.

Phase 1

Not yet recruiting

Conditions: Dry Eye Syndromes
Dry Eye
Dry Eyes Chronic

Interventions: Drug: Systane Ultra®
Drug: PRO-190

First Posted Date: 2024-04-23

Last Posted Date: 2025-03-19

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 32

Registration Number: NCT06379685

Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®

Phase 1

Not yet recruiting

Conditions: Dry Eye Disease
Dry Eye Sensation
Ocular Surface Disease

Interventions: Drug: Optive®
Drug: PRO-240

First Posted Date: 2024-04-19

Last Posted Date: 2025-03-19

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 32

Registration Number: NCT06375343

Study of Non-inferiority Between Manzanilla Sophia® and Meticel Ofteno® 0.5% for Providing a Soothing Sensation to the Eyes.

Phase 4

Withdrawn

Conditions: Eye Strain of Both Eyes
Eye Strain

Interventions: Drug: Manzanilla Sophia®
Drug: Meticel Ofteno®

First Posted Date: 2024-04-18

Last Posted Date: 2025-02-14

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 100

Registration Number: NCT06373653

Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF

Phase 1

Completed

Conditions: Ocular Surface Disease
Dry Eye Disease

Interventions: Drug: PRO-229
Drug: Lagricel® Ofteno PF

First Posted Date: 2024-04-17

Last Posted Date: 2025-03-04

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 36

Registration Number: NCT06370585

Locations: 🇲🇽
Asociacion Mexicana para la Investigacion Clinica, Pachuca de Soto, Hidalgo, Mexico

Study to Evaluate the Safety and Tolerability of PRO-231 Ophthalmic Solution Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects.

Phase 1

Recruiting

Conditions: Ophthalmological Agent Toxicity
Bacterial Conjunctivitis

Interventions: Drug: PRO-231
Drug: VIGAMOXI®

First Posted Date: 2024-04-12

Last Posted Date: 2024-04-15

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 36

Registration Number: NCT06363292

Locations: 🇲🇽
IIMET Investigación e Innovación en Medicina Traslacional, Guadalajara, Jalisco, Mexico

Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.

Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Drug: PRO-232
Other: Placebo

First Posted Date: 2024-04-08

Last Posted Date: 2025-03-20

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 28

Registration Number: NCT06352541

Safety and Tolerability Evaluation of PRO-230 Ophthalmic Solution

Phase 1

Withdrawn

Conditions: Myopia

Interventions: Drug: Atropine Sulfate

First Posted Date: 2022-08-01

Last Posted Date: 2024-07-01

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Registration Number: NCT05481489

Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201

Phase 1

Completed

Conditions: Myopia

Interventions: Drug: Atropine Sulfate

First Posted Date: 2022-07-22

Last Posted Date: 2023-12-06

Lead Sponsor: Laboratorios Sophia S.A de C.V.

Target Recruit Count: 29

Registration Number: NCT05470881

Locations: 🇲🇽
IIMET Investigación e Innovación en Medicina Traslacional, Guadalajara, Jalisco, Mexico

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy